Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05501769
Title ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer (TACTIVE-E)
Acronym TACTIVE-E
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Arvinas Estrogen Receptor, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ESP


No variant requirements are available.